Compare · MDT vs NXL
MDT vs NXL
Side-by-side comparison of Medtronic plc. (MDT) and Nexalin Technology Inc. (NXL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDT and NXL operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT is the larger of the two at $105.19B, about 9466.2x NXL ($11.1M).
- Over the past year, MDT is down 6.2% and NXL is down 59.3% - MDT leads by 53.1 points.
- MDT has been more active in the news (18 items in the past 4 weeks vs 4 for NXL).
- MDT has more recent analyst coverage (25 ratings vs 0 for NXL).
- Company
- Medtronic plc.
- Nexalin Technology Inc.
- Price
- $81.63-0.35%
- $0.48-4.93%
- Market cap
- $105.19B
- $11.1M
- 1M return
- +5.19%
- +37.60%
- 1Y return
- -6.20%
- -59.31%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- News (4w)
- 18
- 4
- Recent ratings
- 25
- 0
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest MDT
- Medtronic upgraded by BTIG Research with a new price target
- Medtronic submits 510(k) filings to expand Hugo™ robotic-assisted surgery system into general and gynecologic specialties in the United States
- Medtronic announces strategic investments to support future expansion of cardiac ablation portfolio as physician demand for Affera™ technologies broadens
- Medtronic plc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Medtronic reports fourth quarter and full year fiscal 2026 results; delivers highest annual revenue growth in 10 years
- morph Launches the World's First Shapeshifting Soft Robotics Cells Platform to Bring Physical AI into Real-World Applications
- SVP, Chief HR Officer Walter Matthew R. converted options into 9,149 units of Ordinary Shares, increasing direct ownership by 28% to 41,529 units (SEC Form 4)
- EVP & Pres Neuroscience Wall Brett A. converted options into 26,907 units of Ordinary Shares, increasing direct ownership by 49% to 82,183 units (SEC Form 4)
- Chairman and CEO Martha Geoffrey converted options into 94,963 units of Ordinary Shares, increasing direct ownership by 38% to 343,099 units (SEC Form 4)
- EVP, Pres MedSurg and Americas Marinaro Michael converted options into 18,994 units of Ordinary Shares, increasing direct ownership by 37% to 70,593 units (SEC Form 4)
Latest NXL
- Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia
- Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury
- Nexalin Technology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
- Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial
- SEC Form 10-Q filed by Nexalin Technology Inc.
- Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia
- Nexalin Technology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Nexalin Advances FDA Alzheimer's Strategy Following Landmark Leadership Meetings in the U.S. and China
- Join Nexalin's Exclusive Live Investor Webinar and Q&A Session on April 21
- Nexalin Announces Peer-Reviewed Study Showing the Company's DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents